Jump to main content
Jump to site search
Access to RSC content Close the message box

Continue to access RSC content when you are not at your institution. Follow our step-by-step guide.


Issue 62, 2014
Previous Article Next Article

Albumin–graphene oxide conjugates; carriers for anticancer drugs

Author affiliations

Abstract

In order to improve its biological properties, graphene oxide can be modified with hydrophilic polymers. Therefore, in this study, the surface of graphene oxide was modified with polyethylene glycol and albumin by covalent methods. In the subsequent step, paclitaxel which is a hydrophobic anticancer drug was loaded onto the surface of the functionalized graphene by π–π interactions. The synthesis of the nanocarrier and its interaction with paclitaxel were evaluated by FT-IR, CD, TEM, UV, AFM, DLS and fluorescence experiments. Release of the loaded drug from albumin–graphene conjugate was investigated at pH 5.4, 6.8 and 7.4.

Graphical abstract: Albumin–graphene oxide conjugates; carriers for anticancer drugs

Back to tab navigation

Article information


Submitted
14 Jun 2014
Accepted
09 Jul 2014
First published
09 Jul 2014

RSC Adv., 2014,4, 33001-33006
Article type
Paper

Albumin–graphene oxide conjugates; carriers for anticancer drugs

S. Jokar, A. Pourjavadi and M. Adeli, RSC Adv., 2014, 4, 33001
DOI: 10.1039/C4RA05752J

Social activity

Search articles by author

Spotlight

Advertisements